Chronic obstructive pulmonary disease (COPD) is a long-term, progressive lung disease that can make breathing challenging. Tobacco smoking is the primary cause of COPD, but other factors can be responsible, for example:1
- Genetics
- Outdoor and indoor air pollution
- Workplace exposures

Image Credit: CI Photos/Shutterstock.com
The challenge of early COPD diagnosis
COPD is often detected late, with Asthma + Lung UK noting that five years is the standard wait for a diagnosis, with provider, patient, and systemic elements influencing this prolonged timeline.2
COPD is a condition that slowly worsens, with clinical signs like breathlessness not emerging until extensive damage to the lungs has already developed. Typically, this does not become noticeable in patients until they reach their forties, fifties, or even beyond.3
Smokers tend to rationalize their physical complaints, tolerating them due to their tobacco use. Another barrier is that initial signs can mirror other ailments, such as allergies, asthma, and other pulmonary conditions.4
Early diagnosis can greatly improve patient outcomes by facilitating treatments that can limit lasting damage to the lungs, but with individuals dismissing initial signs and widespread unfamiliarity with COPD, it is highly probable for early identification to be missed.
Exposure to smoking is the leading preventable risk factor
Smoking is understood to account for 90% of COPD diagnoses,1 with toxic compounds in cigarette smoke harming the lining of the airways and lungs.
Individuals do not necessarily need to have been a smoker to be affected by these damaging chemicals either; certain studies report that passive smoking or contact with the cigarette smoke of other people can heighten clinical risk of COPD.1
This underscores the importance of knowing patients’ smoking histories and exposure to smoke, as decreasing the exposure will help decrease the likelihood of having COPD.
Why self-reported smoking history can be inadequate
Over the years, smoking has become regarded as a taboo practice. As a result, individuals may be reluctant to fully disclose their true smoking history, which can lead to inaccurate self-reporting.
Smoking routines can adapt over the years too; in stressful times or periods in which routines change, users may smoke significantly more.
This is why demand exists for more accurate techniques to analyze the smoking status of a patient in full and help healthcare clinicians grasp the smoking exposure of a patient more effectively.
The purpose of carbon monoxide testing
Carbon monoxide (CO) is a dangerous gas present in tobacco smoke that is breathed in during smoking. CO is measurable in exhaled breath, with elevated concentrations indicating a patient’s exposure to cigarette smoke.
CO monitoring tools, including the Smokerlyzer® series, equip medical practitioners with a reliable tool to determine a patient’s smoking status, opening up clinical dialogue and aiding risk profiling.
A CO reading using the Smokerlyzer® is fast and straightforward, delivering a non-invasive approach to evaluate CO levels.
Faster detection begins with improved smoking assessment
Assessing smoking status is a critical piece of the puzzle, and being equipped with reliable instruments like the Smokerlyzer® to quantify CO exposure aids in noticing high-risk patients early and helps medical practitioners to consider the early indicators of COPD and take appropriate action to boost patient outcomes.
References and further reading
- NHS (2023) Causes - chronic obstructive pulmonary disease (COPD). Available at: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/.
- Asthma + Lung UK A quarter of people with COPD waiting 5 years for a diagnosis. Available at: https://www.asthmaandlung.org.uk/media/press-releases/quarter-people-copd-waiting-5-years-diagnosis.
- NHS (2023) Symptoms - chronic obstructive pulmonary disease (COPD). Available at: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/.
- Thornber, K. (2025) Breaking barriers: why COPD diagnosis is often delayed. European Medical Journal. Available at: https://www.emjreviews.com/respiratory/news/breaking-barriers-why-copd-diagnosis-is-often-delayed/.
About Bedfont® Scientific Ltd
Bedfont® Scientific has specialized in the design and manufacture of exhaled breath and gas monitoring instruments since 1976.
For medical gas monitoring, their Medi-Gas Check medical pipeline testing range verifies not only the quantity but also quality of gas administered to patients.
Bedfont's breath analyzers include carbon monoxide (CO) monitors such as the Smokerlyzer®, used for smoking cessation, and the ToxCO®, used by emergency services, to diagnose CO poisoning.
The NObreath® FeNO monitor provides accurate analysis of airway inflammation for the control of asthma, and the Gastrolyzer® range aids in the detection of gastrointestinal disorders and food intolerances. Quick and non-invasive, breath analysis is the new blood test.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.